Furuya, Hideki https://orcid.org/0000-0002-9536-8662
Sakatani, Toru
Tanaka, Sunao
Murakami, Kaoru
Waldron, Richard T.
Hogrefe, Wayne
Rosser, Charles J.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms
https://doi.org/10.1186/s12967-023-04811-2
Documents that mention this clinical trial
Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms
https://doi.org/10.1186/s12967-023-04811-2
Documents that mention this clinical trial
Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms
https://doi.org/10.1186/s12967-023-04811-2
Documents that mention this clinical trial
Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms
https://doi.org/10.1186/s12967-023-04811-2
Funding for this research was provided by:
National Institutes of Health (R01 CA1988887, UH3 CA271377, R01 CA277810)
Article History
Received: 18 November 2023
Accepted: 16 December 2023
First Online: 2 January 2024
Declarations
:
: This study received approval and a waiver of consent to use previously banked de-identified urine samples from the Cedars-Sinai Medical Center Institutional Review Board, Los Angeles, CA (IRB #00001459). Study performance complied with the tenets of the Declaration of Helsinki.
: Not applicable.
: CJR and WH are officers at Nonagen Bioscience Corporation (Los Angeles, CA, USA), the Oncuria assay manufacturer.